Vitamin B3: Niacin and transcriptome analysis in relation to the GPR109A receptor

Allison Bridges, Pragya Rajpurohit, Puttur D. Prasad, Muthusamy Thangaraju

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

GPR109A is a receptor for niacin or nicotinic acid, which has been utilized as an antidyslipidemic drug for several decades without its mechanism being fully understood. Following the identification of GPR109A, it was determined that the receptor was expressed not only in adipocytes but also in spleen, immune cells, colon, retinal pigment epithelial cells, and breast tissue as well. GPR109A activation has been shown to have more than just an effect on lipids, also promoting tissue-specific regulation of metabolism and inflammation. The antiinflammatory role of GPR109A has been demonstrated in many different tissue types, potentially improving disease states from Parkinson’s disease to diabetic retinopathy. In particular, its impact on colon and breast cancer suggests that GPR109A functions as a tumor suppressor. Therefore GPR109A may prove to be a potential target for future cancer prevention strategies.

Original languageEnglish (US)
Title of host publicationMolecular Nutrition
Subtitle of host publicationVitamins
PublisherElsevier
Pages673-690
Number of pages18
ISBN (Electronic)9780128119075
ISBN (Print)9780128119365
DOIs
StatePublished - Jan 1 2019

Keywords

  • Antidyslipidemic drug
  • Breast cancer
  • Butyrate
  • Cancer therapeutic target
  • Colon cancer
  • GPR109A
  • Inflammation
  • Niacin

ASJC Scopus subject areas

  • Engineering(all)
  • Agricultural and Biological Sciences(all)

Fingerprint Dive into the research topics of 'Vitamin B3: Niacin and transcriptome analysis in relation to the GPR109A receptor'. Together they form a unique fingerprint.

  • Cite this